Abstracts A195 10, with 10 being death). For most patients, MS will progress from an episodic disorder (relapsing-remitting MS) to a more progressive state (secondary progressive MS). We conducted a systematic review of the literature to determine how health related quality of life, as measured by health utilities, changes with the increasing neurological disability associated with different stages of MS. METHODS: Employing pre-defi ned search terms and inclusion/exclusion criteria, systematic searches were conducted in MEDLINE, EMBASE, PsycINFO, Health Economic Evaluation Database (HEED), NHS Economic Evaluations Database (NHS/EED), and the UK National Institute for Health and Clinical Excellence (NICE) website. All databases were searched from 1 January 1993 to 5 August 2008. Data extraction was validated by an independent reviewer. RESULTS: We identifi ed 16 studies reporting health utilities associated with health states of MS. EQ-5D was the most common preference elicitation instrument. Health utilities ranged from 0.80 to 0.89 for patients with an EDSS score of 1, from 0.49 to 0.71 for patients with an EDSS score of 3, from 0.39 to 0.54 for patients with an EDSS score of 6.5, and from 0.19 to 0.08 for patients with an EDSS score of 9 with some patients valuing their health states as worse than death. CONCLUSIONS: MS has a signifi cant impact on quality of life. Utilities decrease signifi cantly with increasing neurological disability. Without taking into consideration EDSS score, there appears to be no difference in health utilities between RRMS and SPMS patients and the variation in health utilities appears to be mainly explained by the severity of the disability. Utilities also decreased signifi cantly during relapse phases.
PND29 CANADIAN PATIENT SURVEY TO ASSESS PATIENTS' PLIGHT TO MOVEMENT DISORDER DIAGNOSES AND BOTULINUM TOXIN TYPE-A (BONTA) TREATMENT -FINAL RESULTS
Simonyi S 1 , Jog M 2 , The Canadian Movement Disorders Survey Group N y p 3 1 Allergan, Inc., Markham, ON, Canada, 2 London Health Sciences Centre, London, ON, Canada, 3 ', ', Canada OBJECTIVES: To assess and describe the diagnostic and treatment pathways of movement disorders responsive to BoNTA, Allergan Units and assess the types and number of health care professionals seen by patients before their movement disorder diagnosis was made and the length of time from onset of symptoms to diagnosis. METHODS: Patients with movement disorders completed a 19-question survey developed by the Canadian Movement Disorders Survey Group. Questions included patient demographics, length of time from onset of symptoms, number and types of physicians seen, other diagnoses made, number of patients treated with BoNTA and distance traveled. RESULTS: In this fi nal analysis, 879 patients with movement disorders responsive to BoNTA were surveyed. Majority of the patients were female (72%), traveling an average of 69 km one-way. Most common movement disorder diagnoses were cervical dystonia (42%), hemifacial spasm (20%), and blepharospasm (9%). Common diagnoses made prior to the movement disorder diagnoses were nerve/muscle problem (33%), stress/psychological problem (39%), tremor (16%), fi bromyalgia (14%), TMJ (10%), joint/tendon problem (15%) and spine (10%). The average number of physicians seen before the movement disorder diagnosis was 3.1. Amongst these were family physicians (78%), neurologists (71%), movement disorder specialists (32%), chiropractors (17%), eye care doctors (17%), physiotherapists (17%), and neurosurgeons (10%). Most physicians who made the current movement disorder diagnoses were neurologists (63%) and movement disorder specialists (33%). The average time in years from onset of symptoms to movement disorder diagnosis were: cervical dystonia 6.6, blepharospasm 4.7, hemifacial spasm 3.8, spasmodic dysphonia 2.5, limb dystonia 8.2, Meige syndrome 2.8, generalized dystonia 1.6, oromandibular dystonia 2.1. 95% of patients were treated with BoNTA following their movement disorder diagnosis. CONCLUSIONS: The number of physicians seen and length of time from onset to movement disorder diagnoses are considerable. Increased awareness of movement disorders at the primary care level may improve these rates.
PND30 DATA ANALYSIS OF PEDIATRIC INPATIENTS DIAGNOSED WITH BRAIN ABSCESS
Redd R University of Louisville, Louisville, KY, USA OBJECTIVES: Brain abscess is a somewhat rare condition found more commonly in pediatric patients than young adults. While fatalities as a result of brain abscesses have decreased signifi cantly in recent years, the possibility of the condition being fatal is very real. Early diagnosis and treatment are the keys to effectively resolving the issue. The purpose of this paper is to examine patient outcomes for those diagnosed with brain abscess. METHODS: Data were taken from the National Inpatient Sample (NIS). The data consist of pediatric patients diagnosed with brain abscesses (N 252) and a randomly selected control group (N 260). SAS Enterprise Guide, a statistical software program, was used to analyze the data set and provide an overview of the results. Methods used included one-way frequencies, statistical summaries, kernel density estimations, and linear and logistic regression models. RESULTS: Contrary to other sources, the age of pediatric patients in the sample seems to play a role in the likelihood of developing brain abscesses. Factors such as age, gender, and race were shown by several different methods to be not signifi cant in the diagnosis. The mortality rate was found to be fi ve times higher in the treatment group than the control suggesting that while this condition may be declining with respect to deaths, the rate is still signifi cantly higher than a random control group from the NIS database. CON-CLUSIONS: While the mortality rate for brain abscesses is low, current procedures can still be improved to lower the rate further. New techniques of diagnosing brain abscesses can also be developed with the research found in the NIS. Further studies should be performed in order to fi nd more relationships. Finding the connection between these connections may lead to better preventive measures and improved treatments for brain abscesses.
PND31 FACTORS ASSOCIATED WITH HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS RECEIVING NATALIZUMAB
Stephenson JJ 2 , Rajagopalan K 3 , Kamat S 2 1 Biogen Idec Pharmaceuticals, Wellesley, MA, USA, 2 HealthCore, Inc., Wilmington, DE, USA, 3 Biogen Idec Pharmaceuticals, Cambridge, MA, USA OBJECTIVES: To assess factors associated with health-related quality of life (HRQoL) in MS patients after three natalizumab infusions. METHODS: MS patients, newly enrolled in the manufacturer's restricted drug distribution program and participating in a longitudinal study of their experiences with natalizumab, complete assessments prior to treatment initiation and after the 3 rd , 6 th and 12 th infusion. HRQoL was assessed with the SF-12v2 where higher physical and mental component summary (PCS and MCS) scores indicated improvement in HRQoL. Univariate, followed by multivariate, linear regression was used to identify factors associated with HRQoL after three natalizumab infusions. The factors used in this analysis include age, clinical characteristics (disease duration, number of prior MS treatments) and baseline (BL) disease severity measures (disease step (DS), functional status, fatigue score, cognitive functioning (CF) score). RESULTS: At the time of this analysis 504 patients had completed BL and 3 rd assessments. Mean age was 46.08 10.93, 78% of patients were female, and mean disease duration was 9.64 8.33 years. PCS and MCS scores improved signifi cantly from baseline (PCS: 34.03 versus 36.02; p 0.001) and MCS: 43.17 versus 47.22; p 0.001). Multivariate analysis indicated that higher BL PCS scores (p 0.001), lower BL DS scores (p 0.001) and younger age (p 0.002) were associated with improvement in PCS scores after three natalizumab infusions. Similarly, higher BL MCS (p 0.001) and BL CF scores (p 0.001) were associated with improvement in MCS scores after the 3 rd infusion. CONCLUSIONS: Factors associated with improvement in PCS scores after the 3 rd infusion were younger age, higher BL PCS scores, and lower BL DS scores (better ambulation) while those associated with improvements in MCS scores were higher BL MCS scores and higher BL CF scores. These results suggest that initiating natalizumab in younger patients having lower disability and better baseline HRQoL results in greater improvements in HRQoL after three natalizumab infusions.
